Six strategies, a full Opportunity Zone deep-dive, and a guide to what doesn't work — everything a healthcare practice seller needs to understand before closing.
For most healthcare practice owners, the largest single tax event of their lives is the sale of their business. On a $5M transaction, federal capital gains taxes alone can exceed $750,000 — before state taxes are added. Yet most sellers approach closing with little understanding of the legal structures that can defer, reduce, or in some cases eliminate that bill. This white paper covers the six primary strategies in plain terms, with precise descriptions of what each accomplishes under current federal law. None of these strategies is a loophole. Each is expressly authorized by the Internal Revenue Code. What separates sellers who use them from those who don't is almost always the quality of their advisors — and how early the planning begins.
In a straightforward asset sale — no rollover, no installment deferral, no allocation optimization — a materially participating S-Corporation owner selling a $5M practice will typically owe federal tax on five distinct pools of gain, each taxed differently:
| Asset Category | Typical Allocation | Federal Tax Character | Max Federal Rate |
|---|---|---|---|
| Goodwill & Going-Concern Value | 65–80% of total proceeds | Long-Term Capital Gain (if held >12 months) | 20% |
| Accounts Receivable | 3–8% | Ordinary Income (IRC §751 "hot assets") | 37% |
| Non-Compete Agreement | 5–10% | Ordinary Income | 37% |
| Tangible Equipment / FF&E | 3–8% | §1245 Depreciation Recapture (ordinary income) | 37% |
| Real Property (if included) | Varies | Unrecaptured §1250 gain (special capital gain rate) | 25% |
The NIIT Note: Many sellers are told to expect a 23.8% LTCG rate (20% + 3.8% NIIT under IRC §1411). This is accurate for passive investors but typically does not apply to the active owner-operator. The 3.8% Net Investment Income Tax under IRC §1411 is carved out for taxpayers who materially participate in the business under IRC §469. For the hands-on practice owner, the effective LTCG rate on goodwill is generally 20% — not 23.8%. Confirm your material participation status with a qualified CPA before assuming either rate applies to you.
In most PE-backed healthcare acquisitions, the buyer asks the seller to retain a minority equity stake — typically 20–30% — rather than receiving full cash at close. Without structural planning, this rollover creates a problem: the seller must recognize gain on the entire deal, including the portion they haven't actually received in cash. The F-Reorganization solves this.
The seller recognizes gain on 100% of deal value — including the rollover stake — in the year of closing. Tax is owed on proceeds not yet received. On a $5M deal with 30% rollover, the seller owes LTCG tax on $1.5M they won't receive until the platform sells years later.
Tax on the rollover portion is fully deferred until the seller exits the platform at the second-event sale. Only the cash portion is taxed at closing. The deferred gain carries over into the new equity and is recognized — at LTCG rates — upon the platform sale.
The seller contributes their S-Corp stock into a newly formed holding company. This is treated as a non-taxable reorganization under IRC §368(a)(1)(F) — a "mere change in identity or form." The IRS views Newco as a continuation of the original entity.
The target entity converts into a disregarded LLC under Newco. This is also a non-taxable event. Newco now owns the operating LLC. This conversion typically occurs at least one day after the F-Reorg steps to satisfy IRS requirements.
The buyer acquires the cash portion of the deal by purchasing the seller's interest in the LLC. For tax purposes this is treated as an asset acquisition — the buyer receives a full basis step-up on the purchased percentage, equivalent to a pure asset deal.
The rollover stake is contributed to the buyer's partnership or LLC in exchange for equity units. Under IRC §721, contributions to a partnership in exchange for a partnership interest are generally non-taxable. The deferred gain carries over and is recognized only at exit.
Tax Savings Illustration: On a $5M deal with 30% rollover, the F-Reorg defers tax on approximately $1.5M of gain to the second-event sale. At a 20% LTCG rate, that is ~$300,000 deferred — money that remains invested and compounding in the platform for 4–7 years before the bill comes due. And if the platform appreciates from a $5M entry to a $10M platform exit, the deferred gain plus appreciation is still taxed at LTCG rates — not as ordinary income. Important caveats: Anti-churning rules under IRC §197(f) must be analyzed if the seller retains more than 20% of the buyer post-close and the goodwill predates 1993. State conformity to F-Reorg treatment varies. The rollover gain is deferred — not eliminated — and will be recognized at exit. This structure requires a qualified tax attorney and CPA working in coordination.
When part of the purchase price is paid over time — via an earnout, seller note, or deferred consideration — IRC §453 installment sale treatment applies automatically when at least one payment is received after the tax year of sale. This is the default method under federal law; sellers who do not want installment treatment must affirmatively elect out by the due date of their return (including extensions) for the year of sale. Under the installment method, the seller recognizes gain proportionally as payments are received, spreading tax liability across multiple tax years.
The Escrow Timing Advantage: Standard PE deals include 12–24 months of escrow on roughly 15–20% of the cash consideration. Under IRC §453, this escrow is typically not taxable until released. On a $5M deal with $750,000 in escrow, the seller defers recognition of that portion — and the associated tax — until the escrow release, allowing a portion of the tax bill to land in a subsequent calendar year. Coordinate escrow release timing with your CPA before closing.
Under IRC §1060, both buyer and seller must allocate the purchase price across seven asset classes using the IRS residual method and file consistent Form 8594 allocations. Each class carries different tax treatment — and the allocation is negotiated between the parties. This is not a passive outcome. It is the most direct lever a seller has over their effective tax rate.
| IRC §1060 Class | Typical Assets | Seller Tax Treatment | Buyer Preference |
|---|---|---|---|
| Class I — Cash & Cash Equivalents | Bank accounts, cash on hand | No gain — basis equals FMV | Neutral |
| Class II — Securities | Certificates of deposit, government securities | Capital gain at applicable rate | Neutral |
| Class III — Accounts Receivable | Billed but uncollected revenue | Ordinary income — up to 37% | Higher (deductible immediately) |
| Class IV — Inventory | Medical supplies, durable goods | Ordinary income | Higher (deductible immediately) |
| Class V — Other Tangible Assets | Equipment, furniture, leasehold improvements | §1245 recapture (ordinary income) to extent of prior depreciation; excess is LTCG | Higher — equipment depreciates over 5–7 years under MACRS (vs. 15-year §197 amortization for goodwill), and may qualify for immediate expensing under §179 or bonus depreciation |
| Class VI — Intangibles (non-§197) | Non-compete agreements, assembled workforce | Ordinary income — non-competes taxed as OI; workforce intangibles may qualify as LTCG | Neutral to lower — non-competes amortize over 15 years under §197, the same as goodwill; buyer gains no depreciation advantage over Class VII |
| Class VII — Goodwill & Going-Concern | Practice reputation, patient relationships, brand value | Long-Term Capital Gain at 0%, 15%, or 20% | Lower (15-year §197 amortization) |
Seller's Goal: Maximize Class VII (Goodwill) allocation. Every dollar shifted from a non-compete or A/R (taxed at 37%) to goodwill (taxed at 20%) saves 17 cents of federal tax per dollar — on a $1M non-compete payment versus goodwill, that is $170,000 in federal tax savings. Buyers prefer the opposite allocation for depreciation and amortization purposes. The final allocation is a negotiated outcome. Sellers who engage M&A counsel and tax advisors with experience in these negotiations consistently achieve better allocations than those who accept buyer-drafted Form 8594 terms without scrutiny.
The Qualified Opportunity Zone (QOZ) program is a post-sale reinvestment strategy: after a practice sale closes, the seller invests eligible capital gains proceeds into a Qualified Opportunity Fund (QOF) within 180 days. This is the most complex of the six strategies — with materially different rules depending on when the investment is made, which gains qualify, and which state the seller lives in. A full deep-dive follows after Strategy 06.
See the full Opportunity Zone deep-dive below — covering eligible vs. ineligible gains asset-by-asset, the 180-day clock rules, Phase 1 vs. Phase 2 differences, worked dollar examples, state conformity by state, what QOFs actually invest in, and due diligence guidance.
A Charitable Remainder Trust (CRT) is an irrevocable trust that allows a seller to transfer appreciated assets — including a business interest — into a trust that sells the asset without paying immediate capital gains tax. The trust pays the grantor (and/or other named beneficiaries) an income stream for life or a fixed term of up to 20 years. When the income period ends, the remaining trust assets pass to one or more designated charities.
The seller transfers the appreciated business interest (or a portion of it) into the CRT well before any sale process is underway. This timing requirement is far more demanding than sellers typically expect. The IRS applies the "prearranged sale" (anticipatory assignment of income) doctrine: if the sale has become a "practical certainty" by the date of contribution — even without a signed contract — the IRS will attribute the gain to the donor personally and disallow the CRT's tax-exempt sale treatment, negating all benefits. In the 2023 Tax Court case Estate of Hoensheid v. Commissioner, a gift of stock to charity was disallowed because the sale was already practically certain even though no binding agreement existed. In an M&A context, a seller who is already in an active auction process, has received LOIs, or is in exclusivity almost certainly cannot contribute assets to a CRT and achieve the intended deferral. CRTs must be established and funded before a sale process is meaningfully underway — not at signing, not at LOI, not during due diligence.
The CRT is a tax-exempt entity under IRC §664. When the trust sells the business interest, it does not pay capital gains tax. The full proceeds are retained in the trust and reinvested, compounding without immediate tax friction.
The grantor receives annual payments from the trust (as an annuity or unitrust amount). Under IRC §664(b)'s four-tier accounting system, these distributions carry out income in a specific order: ordinary income first, then capital gains, then tax-exempt income, then return of principal. Capital gains embedded in the trust are recognized gradually as distributions are made — not all at once in the year of sale.
The grantor receives an income tax deduction in the year the CRT is funded, based on the actuarial present value of the remainder interest passing to charity. The deduction is limited to 30% of AGI for contributions of appreciated property (with a 5-year carryforward for excess deductions). This deduction can partially offset the ordinary income wedge from A/R and non-compete payments that cannot be deferred.
Important Structural Limitations: A CRT is irrevocable. Once the trust is funded, the grantor cannot access the principal directly, change the charitable beneficiary, or modify the income distribution amount. The trust commitment — and the charitable component — are permanent. CRTs are most appropriate for sellers with genuine philanthropic intent, since the balance ultimately passes to charity rather than to heirs. Setup costs (legal drafting, actuarial calculations, ongoing trustee fees) are typically several thousand dollars annually. This strategy requires careful coordination between an M&A advisor, estate planning attorney, and CPA.
The simplest and most overlooked LTCG reduction strategy in an M&A context is harvesting existing capital losses from a seller's investment portfolio to offset deal gains. Under IRC §1211 and §1212, capital losses offset capital gains dollar-for-dollar on a federal return, with up to $3,000 of excess losses available to offset ordinary income annually and unlimited carryforward of remaining losses.
A Qualified Opportunity Zone (QOZ) is an economically distressed census tract nominated by each state's governor and certified by the U.S. Treasury Secretary. There are currently 8,764 designated zones across the United States and its territories. The QOZ program — created by the 2017 Tax Cuts and Jobs Act and made permanent by the One Big Beautiful Bill Act (OBBBA) in July 2025 — allows taxpayers who realize certain capital gains to defer, reduce, and in some cases eliminate federal tax on those gains by reinvesting in a Qualified Opportunity Fund (QOF) within a strict window after the gain-triggering sale.
A QOF is an investment vehicle organized as a corporation or partnership — not a direct real estate investment or a bank account — that holds at least 90% of its assets in Qualified Opportunity Zone property (tested semi-annually). The QOF then deploys capital into real estate development or operating businesses within designated zones. Investors do not invest directly into zone property; they acquire an equity interest in the QOF.
The Core M&A Relevance: The QOZ program does not restructure a business sale transaction itself. It is a post-sale reinvestment strategy: after a healthcare practice is sold and gain is recognized, the seller takes the after-sale capital gains proceeds and reinvests them into a QOF within 180 days. The sale, purchase price allocation, F-Reorganization, and all other deal mechanics are entirely separate from — and unaffected by — the QOF election.
The QOZ program offers three separate and distinct tax benefits, which compound over time. These benefits are independent of each other and apply to different pools of gain.
When an eligible gain is invested into a QOF within the 180-day window, the taxpayer elects to defer recognition of that gain. Under Phase 1 (original program), this deferral ends on the earlier of: (a) when the QOF interest is sold or exchanged, or (b) December 31, 2026. Under Phase 2 (post-2026 program), the deferral period is a rolling 5 years from the investment date. Deferral does not eliminate the original gain — it postpones it.
Investors who hold the QOF investment for at least 5 years receive a 10% increase in basis on the original deferred gain, permanently excluding that portion from taxation. Under Phase 1, a 7-year hold adds another 5% (15% total) — but both step-ups are now expired for new Phase 1 investments. Under Phase 2, a 5-year hold yields a 10% step-up for standard QOFs, or 30% for qualifying rural QROFs. There is no 7-year tier under Phase 2 for standard QOFs.
If the investor holds the QOF investment for at least 10 years and then sells, the investor can elect to step up the basis of the QOF interest to its fair market value on the sale date — eliminating all federal capital gains tax on appreciation generated during the holding period. This benefit applies to both Phase 1 and Phase 2 investments. Critically: this exclusion applies only to appreciation inside the QOF after the investment date — not to the original deferred gain itself.
Putting It Together: A seller who invests $1M of LTCG proceeds into a QOF in early 2027 (Phase 2) and holds for 10+ years: (1) defers the $1M gain for 5 years; (2) receives a 10% basis step-up, so only $900,000 of the original gain is recognized at LTCG rates in year 5; and (3) pays zero federal tax on whatever the QOF investment grew to above $1M. The original $900K of recognized gain is still taxed. The growth above that is not.
Not all proceeds from a business sale are eligible for QOF deferral. In a typical healthcare practice asset sale, a meaningful portion of proceeds cannot be deferred regardless of how quickly they are reinvested.
| Asset / Gain Type | Tax Character | QOF-Eligible? | Why |
|---|---|---|---|
| Goodwill & Going-Concern (held >12 months) | Long-Term Capital Gain | ✓ Eligible | Capital gain recognized before Jan. 1, 2027 from an unrelated party transaction qualifies under IRC §1400Z-2(a)(1) |
| Accounts Receivable (A/R) | Ordinary Income (IRC §751 hot asset) | ✗ Ineligible | IRS FAQ A29 explicitly: "Ordinary gain is not eligible for deferral." |
| Non-Compete Agreement Payments | Ordinary Income | ✗ Ineligible | Ordinary income. Cannot be deferred into a QOF under any circumstances. |
| §1245 Depreciation Recapture (equipment) | Ordinary Income | ✗ Ineligible | IRS Form 4797 instructions: "Sections 1245 and 1250 gain may not be deferred into a QOF." |
| §1231 Gain in excess of §1245/§1250 recapture | Qualified §1231 Gain (capital gain character) | ✓ Eligible | Gross §1231 gains — to the extent they exceed ordinary-income recapture — are eligible per final regulations. |
| Unrecaptured §1250 Gain (real property) | Special capital gain rate (max 25%) | ✓ Eligible | "Unrecaptured" §1250 gain is a subset of §1231 gain, not ordinary income. Eligible for QOF deferral. |
| Short-Term Capital Gains | Short-Term Capital Gain (ordinary rates) | ✓ Eligible | Both short-term and long-term capital gains qualify. Original tax character is preserved at the deferral end date. |
The Practical Impact: On a $5M healthcare practice sale, the purchase price might break down as: $3.5M goodwill (LTCG — eligible), $300K A/R (ordinary — ineligible), $400K non-compete (ordinary — ineligible), $300K equipment recapture (§1245 ordinary — ineligible), and $500K other §1231 gains. The seller cannot defer the $1M of ordinary income items regardless of what they do with those proceeds. Only the capital gain portion is eligible. Sellers who plan their QOF investment assuming all proceeds qualify will face a shortfall.
Only the Gain Amount Needs to Be Invested — Not the Full Proceeds: The QOF election defers only the gain amount. If a seller has $5M in proceeds with $0 basis (common for goodwill), the full $5M is gain. If the seller had $1M of basis, only the $4M gain portion needs to enter the QOF — the remaining $1M return of basis can be deployed freely. The seller can also invest only a portion of eligible gain, partially deferring it.
The 180-day window is the most operationally critical element of the QOF election. Miss it and the deferral benefit is permanently lost for that gain. The clock start date depends on how the gain was generated:
The 180-day period begins on the date of the sale that generates the gain. Most M&A closings fall here. A seller closing on June 1 has until November 28 to invest the eligible gain into a QOF.
Partners, S-corp shareholders, and trust beneficiaries can elect to start the 180-day window on any of three dates: (1) the date of the underlying sale, (2) the last day of the entity's tax year (typically Dec. 31), or (3) the entity's return due date without extensions (typically Mar. 15). This flexibility can significantly extend the reinvestment window.
Each installment payment triggers its own 180-day window starting on the date that payment is received. Alternatively, the seller may elect a single 180-day period beginning on the last day of the tax year in which the sale occurred.
§1231 Gains — Special Default Start Date: For gains from the sale of business property reported on Form 4797, the default 180-day period begins on the last day of the tax year (typically December 31), not the sale date — unless the investor elects to use the actual sale date instead. A seller who closes a practice sale on March 1, 2027 with §1231 gain and uses the default start date begins the QOF clock on December 31, 2027, giving them until June 29, 2028. This default rule provides extra planning time compared to direct capital gain sales.
The rules governing a QOF investment depend entirely on when the investment is made. Healthcare practice sellers who close in 2026 vs. 2027 face substantially different QOZ planning considerations.
The following examples assume a materially participating S-Corp owner with a $5M practice sale generating $4M of LTCG-eligible gain (goodwill) and $1M of ordinary income items (A/R, recapture, non-compete). All figures are illustrative federal-only estimates. Without any QOF investment, the seller would owe $800K on the gain immediately and $600K on appreciation — $1.4M total.
Seller closes in Q2 2026 and invests $4M of eligible LTCG gain into a QOF within 180 days. No basis step-up available (deadline expired). QOF held 10+ years.
Seller closes in Q2 2027 and invests $4M of eligible gain into a standard (non-rural) QOF. Held 10+ years. 5-year step-up applies.
Key Takeaway: In both scenarios, the biggest value driver is the 10-year appreciation exclusion, not the deferral itself. The deferral merely buys time — the exclusion permanently eliminates federal tax on QOF growth. The calculus favors sellers expecting substantial QOF appreciation over a 10-year horizon. Sellers who need liquidity, expect low QOF returns, or cannot hold for 10 years capture far less benefit.
The following pro formas track the same $4,000,000 eligible gain through each scenario on an annual basis — showing QOF fair market value, investor basis, cumulative tax paid, and key tax events at each milestone. Assumptions: 7% annual QOF appreciation (compounded), 20% federal LTCG rate, materially participating S-Corp seller, no state income tax. Both scenarios assume the QOF investment is held for the full 10-year period to capture the appreciation exclusion and is then sold. All figures are federal only and illustrative.
Key Mechanics Reminder: At investment, the investor's basis in the QOF starts at $0 per IRC §1400Z-2. Basis increases only through the step-up provisions (10% of original gain at year 5 under Phase 2; no step-up available in Scenario A). The recognized gain at deferral end is the lesser of (a) the original deferred gain minus basis adjustments, or (b) the QOF's fair market value at the recognition date minus basis. After the deferred gain is recognized and taxed, the investor's basis steps up to equal the amount recognized — so at the 10-year sale, the taxable gain is only appreciation above that basis, which is excluded under the 10-year election.
$4M eligible gain invested in QOF in June 2026. No basis step-up available. Mandatory recognition December 31, 2026. QOF held through June 2036 (10 years), then sold with 10-year appreciation exclusion elected.
| Year / Date | Event | QOF FMV @ 7%/yr |
Investor Basis in QOF |
Gain Recognized This Period |
Tax Due @ 20% LTCG |
Cumulative Tax Paid |
|---|---|---|---|---|---|---|
| Jun 2026 | Investment $4M eligible gain invested in QOF; deferral election filed on Form 8949 | $4,000,000 | $0 Basis starts at zero per §1400Z-2 |
— | — | $0 |
| Dec 31, 2026 | Recognition Mandatory Phase 1 deferral end. Gain recognized = lesser of (a) $4M original gain or (b) QOF FMV ($4,140,000) minus basis ($0). Lesser is $4,000,000. Basis steps up to $4,000,000 post-recognition. | $4,140,000 ~6 months at 7% |
$4,000,000 Steps up = recognized gain |
$4,000,000 | $800,000 Due April 2027 |
$800,000 |
| 2027–2035 | Holding QOF appreciates at 7%/yr. Investor holds — no further tax events. Form 8997 filed annually with tax return. | $4,140,000 → $7,868,860 9.5 yrs of 7% growth |
$4,000,000 No change; no new step-up available |
$0 | $0 | $800,000 |
| Jun 2036 | Exit (10-Yr) QOF sold at $7,868,860. 10-year exclusion elected on Form 8949 — basis steps up to FMV ($7,868,860). Gain on sale = $7,868,860 − $7,868,860 = $0. Appreciation of $3,868,860 above the post-recognition basis of $4M is fully excluded. | $7,868,860 $4M × 1.07^10 |
$7,868,860 Stepped to FMV at sale |
$0 10-yr exclusion |
$0 | $800,000 |
| Scenario A Summary — Total Federal Tax Over Life of Investment |
Tax on original $4M gain$800,000
Tax on $3,868,860 QOF appreciation$0
Total federal tax paid$800,000
Tax saved vs. no QOF (appreciation only)$773,772
|
|||||
Scenario A Note on "Tax Saved": Without any QOF, the seller pays $800K on the original gain immediately in 2026 — the same as Scenario A. The QOF provides no benefit on the original gain (no step-up, near-zero timing advantage). The entire benefit of Scenario A comes from the 10-year appreciation exclusion: $3,868,860 of appreciation that would otherwise be taxed at 20% ($773,772) is eliminated. The total tax bill is identical to a non-QOF investor on the original gain — but the seller keeps the full growth tax-free.
$4M eligible gain invested in QOF in June 2027. 10% basis step-up at 5-year mark. Rolling deferral recognized at Year 5 (June 2032). QOF held through June 2037 (10 years), then sold with 10-year appreciation exclusion elected.
| Year / Date | Event | QOF FMV @ 7%/yr |
Investor Basis in QOF |
Gain Recognized This Period |
Tax Due @ 20% LTCG |
Cumulative Tax Paid |
|---|---|---|---|---|---|---|
| Jun 2027 | Investment $4M eligible gain invested in QOF; deferral election filed on Form 8949. Phase 2 rolling 5-year deferral begins. | $4,000,000 | $0 Basis starts at zero per §1400Z-2 |
— | — | $0 |
| 2028–2031 | Holding QOF appreciates at 7%/yr. No tax events. Form 8997 filed annually. | $4,000,000 → $5,243,184 4 yrs at 7% |
$0 No step-up yet |
$0 | $0 | $0 |
| Jun 2032 (Year 5) |
5-Year Step-Up 5-year holding period met. Basis increases by 10% of original deferred gain: 10% × $4,000,000 = $400,000. This $400K is permanently excluded — never recognized as income. | $5,610,207 $4M × 1.07^5 |
$400,000 Step-up: 10% × $4M |
$0 Step-up event; no recognition yet |
$0 | $0 |
| Jun 2032 (same date) |
Recognition 5-year deferral period ends. Gain recognized = original deferred gain ($4,000,000) minus basis ($400,000) = $3,600,000. Basis steps up by recognized amount: $400,000 + $3,600,000 = $4,000,000 total. | $5,610,207 | $4,000,000 $400K step-up + $3.6M recognized |
$3,600,000 | $720,000 Due April 2033 |
$720,000 |
| 2033–2036 | Holding QOF continues appreciating at 7%/yr. Basis = $4,000,000. No further tax events. Form 8997 filed annually. | $5,610,207 → $7,868,860 5 more yrs at 7% ($5,610,207 × 1.07^5) |
$4,000,000 No change |
$0 | $0 | $720,000 |
| Jun 2037 | Exit (10-Yr) QOF sold at $7,868,860. 10-year exclusion elected — basis steps up to FMV ($7,868,860). Gain on sale = $0. Appreciation of $3,868,860 above the post-recognition basis of $4M is fully excluded. | $7,868,860 $4M × 1.07^10 |
$7,868,860 Stepped to FMV at sale |
$0 10-yr exclusion |
$0 | $720,000 |
| Scenario B Summary — Total Federal Tax Over Life of Investment |
Tax on $3.6M recognized gain (Year 5)$720,000
$400K permanently excluded via step-up$80,000 saved
Tax on $3,868,860 QOF appreciation$0
Total federal tax paid$720,000
Total saved vs. no QOF ($80K + $773,772)$853,772
|
|||||
| Metric | No QOF Investment | Scenario A (Phase 1, 2026) | Scenario B (Phase 2, 2027) |
|---|---|---|---|
| Original gain taxed | $4,000,000 in year of sale | $4,000,000 at Dec. 31, 2026 | $3,600,000 at Year 5 (2032) |
| Tax on original gain | $800,000 | $800,000 | $720,000 |
| Amount permanently excluded via step-up | $0 | $0 | $400,000 |
| When tax on original gain is due | April of sale year | April 2027 (minor deferral) | April 2033 (~6 yrs of deferral) |
| QOF FMV at 10-year exit | N/A | $7,868,860 | $7,868,860 |
| Tax on QOF appreciation at exit | N/A | $0 (10-yr exclusion) | $0 (10-yr exclusion) |
| QOF appreciation excluded | N/A | $3,868,860 | $3,868,860 |
| Total federal tax over investment life | $800,000 + tax on future growth | $800,000 | $720,000 |
| Total saved vs. no QOF | — | $773,772 (appreciation exclusion only) |
$853,772 ($80K step-up + $773,772 exclusion) |
Important Limitation Not Shown: These proformas assume a constant 7% annual return and that the QOF holds and appreciates uninterrupted for 10 years. In practice: QOF returns are not guaranteed; the fund must pass its 90% asset test semi-annually throughout the holding period; inclusion events (sale of the QOF interest, certain pledges, or distributions) trigger early gain recognition and potentially eliminate the 10-year exclusion; and state income taxes are additive and may be owed immediately at the time of sale in non-conforming states like California. Model these scenarios with a qualified CPA using actual deal economics before making any investment decision.
A QOF is an entity — a corporation or partnership — that self-certifies by filing IRS Form 8996 with its annual tax return. A single-member LLC (disregarded entity) cannot be a QOF. Investors can either: (a) invest in an existing sponsor-managed QOF, or (b) establish a "captive" QOF for their own investment. Most sponsor-managed QOFs are offered as private placements under Regulation D and require accredited investor status.
At least 90% of the QOF's assets must be invested in Qualified Opportunity Zone property, tested semi-annually. The QOF has up to 31 months under a working capital safe harbor to deploy capital into qualifying investments — a buffer between when investor capital enters the fund and when it must be deployed into the zone.
Investors must file IRS Form 8997 every year they hold a QOF investment. The deferral election is made on Form 8949 for the tax year of gain recognition. Starting 2026, QOFs and QOZ businesses face new expanded OBBBA reporting obligations — disclosing investments, property, and employment data publicly.
Certain events trigger early recognition of the deferred gain — called "inclusion events." These include: selling or exchanging the QOF interest, certain distributions that reduce the taxpayer's basis, and corporate liquidations involving the QOF. Pledging the QOF interest as collateral can also trigger inclusion. A gift to a grantor trust is generally not an inclusion event.
Most states conform to federal QOZ treatment — but a meaningful number do not, and sellers in non-conforming states may owe state capital gains tax on gains that are federally deferred or excluded.
Why This Matters for Mihama Clients: A Texas-based practice seller captures the full federal QOZ benefit with no state tax. A California-based seller owes California state capital gains tax immediately — on a $4M gain at ~13.3%, that is ~$532,000 due to the state with zero deferral, regardless of the federal QOF election. Always verify current conformity status with a qualified tax professional before making any QOF investment.
To capture the 10-year appreciation exclusion, the investor must hold the QOF interest for 10 full years without triggering an inclusion event. Capital is effectively locked for a decade into real estate or an operating business in a distressed area. Sellers who need capital for retirement income or personal spending face a genuine constraint.
QOZ investing requires entrusting capital to a fund manager who deploys it into QOZ property. Investors in sponsor-managed QOFs have limited input over specific projects, timing, or asset selection. A captive QOF gives more control but requires the seller to identify and manage a qualifying investment themselves.
QOF investments carry real investment risk. If a QOF fails compliance requirements, the investor may lose tax benefits and face penalties. If the QOF declines in value, the investor still owes tax on the original deferred gain — but capped at the lower FMV of the QOF at the deferral end date.
When QOZ Investing Makes Sense: Most compelling for sellers who (1) live in a conforming state, (2) have substantial LTCG-character gain, (3) have genuine 10-year investment horizons, (4) are comfortable with QOF investment risks, and (5) can identify a high-quality QOF. Least compelling for sellers with large ordinary income components, non-conforming state residents, or sellers who need near-term capital flexibility.
Understanding the tax mechanics is one thing. Understanding what you'd actually be putting your capital into is another. QOF investments fall into three broad categories, each with different risk profiles, return expectations, and control levels.
The large majority of retail-accessible QOFs are real estate development funds. A professional fund sponsor identifies qualifying properties inside designated OZ census tracts — typically ground-up multifamily construction, mixed-use development, or substantial rehabilitation of existing commercial buildings — raises capital from investors, and manages the project through development and stabilization. Investors acquire a limited partnership or LLC membership interest and receive annual K-1s.
Typical minimums: Most sponsor-managed QOFs structured as private placements require accredited investor status and carry minimum investment thresholds of $100,000–$500,000. A practice seller investing $2–4M of eligible LTCG gain would typically hold interests across one to a few funds.
A QOF can invest in an operating business (a Qualified Opportunity Zone Business) located and primarily operating within a designated zone. The business must derive at least 50% of its gross income from active conduct within the zone, use at least 70% of its tangible property in the zone, and maintain less than 5% of assets in non-qualified financial property. Certain business categories are prohibited (liquor stores, gambling, golf courses, tanning salons, massage parlors). Healthcare services businesses are not prohibited. Operating business QOFs are less common than real estate funds and require deeper due diligence.
A "captive" QOF is formed by an individual seller, family, or small group specifically to manage their own investment. The seller's attorney and CPA form the QOF entity, self-certify on IRS Form 8996, and the seller identifies and controls the underlying qualifying investment. The seller becomes, in effect, the fund manager. The 31-month working capital safe harbor allows cash to be held inside the QOF while identifying the right project.
The real cost: Running a compliant QOF is not passive. The 90% asset test must be met semi-annually. Form 8996 must be filed annually. The OBBBA adds new disclosure requirements. Sellers choosing a captive structure need experienced QOZ tax counsel.
There are 8,764 designated OZ census tracts under the Phase 1 map (in effect through December 31, 2028), designated in 2018 based on low-income criteria. The map covers a wide spectrum: distressed urban corridors, post-industrial cities, rural counties with persistent poverty, and some neighborhoods that have since gentrified significantly from their 2018 baseline.
A note on "gentrified" OZ tracts: Some originally designated tracts — especially in Austin and parts of other major cities — have appreciated substantially since 2018. The OZ designation does not expire until end of 2028, so investments in these tracts still qualify for QOF treatment even if the neighborhood no longer looks distressed. The qualifying status is based on the 2018 designation, not current conditions.
The tax benefits of a QOF do not change the fundamental nature of the underlying investment. A QOF is an equity stake in a real estate project or operating business — often illiquid for 10 years, with returns depending entirely on the quality of the underlying asset and management. Sellers should evaluate at minimum:
Mihama's Role: Evaluating specific QOF investments — vetting track records, reviewing PPMs, analyzing fund economics — is investment advisory work requiring a registered investment advisor with QOZ expertise. Mihama's role is to ensure sellers understand the mechanics accurately, have modeled their after-tax outcomes, and are connected to the right advisors before committing to a 10-year illiquid position. A seller who invests $3M into a poorly vetted QOF because they were focused on tax deferral has made a significant financial error. The tax benefit is the incentive — investment quality is what determines the outcome.
IRC §1202 is one of the most powerful capital gains elimination tools in the tax code — allowing eligible shareholders to exclude up to 100% of federal capital gains on the sale of Qualified Small Business Stock (QSBS) in a domestic C-Corporation, subject to a cap of the greater of $15 million (as updated by the OBBBA for stock issued after July 4, 2025) or 10 times the seller's adjusted basis. For qualifying sellers who have held stock for at least five years, the federal tax bill on qualifying gain can be zero.
Mihama includes this section because sellers frequently ask about §1202 after hearing about it from advisors or peers in other industries. The answer for virtually all healthcare practice sellers is direct: healthcare services businesses are expressly excluded from QSBS treatment by statute.
IRC §1202(e)(3) expressly excludes from the definition of "qualified trade or business" any business performing services in the field of health — including physician practices, physical therapy clinics, behavioral health practices, dental groups, and most other licensed clinical service providers. The statute's intent is clear: practices where the principal value lies in the clinical expertise and licensure of employees or owners are categorically excluded. The IRS has consistently applied this exclusion broadly to clinical service businesses.
The Edge Case: Healthcare technology and software companies that sell tools to providers — rather than delivering clinical services directly — may qualify as QSBS issuers, since they are not "performing services in the field of health" but rather creating and selling a product used in healthcare. If Mihama's client base ever includes health-tech sellers, §1202 planning should be evaluated with a qualified tax attorney well before any transaction.
Several strategies are commonly mentioned by sellers or general financial advisors that do not apply — or apply very differently — in the context of a business asset sale. Getting these wrong can lead to costly planning errors.
| Common Misconception | What the Law Actually Says |
|---|---|
| "I can do a §1031 like-kind exchange to defer the gain from my practice sale." | No. The Tax Cuts and Jobs Act of 2017 limited §1031 exchanges to real property only. Business assets — including goodwill, equipment, and intangibles — no longer qualify for like-kind exchange treatment. §1031 is available for any real estate held by the practice (clinic buildings, land), but not for the operating business assets that typically represent 85–95% of a healthcare practice's sale price. |
| "If I hold the business until I die, my heirs get a stepped-up basis and the gain disappears." | True in theory — IRC §1014 provides a stepped-up basis to fair market value at death, which can eliminate deferred capital gain for heirs of appreciated assets. But this is an estate planning strategy, not an M&A tax strategy. It requires the owner to hold the asset until death rather than sell it. It does not help a seller who wants to monetize the practice during their lifetime. It is also subject to ongoing legislative risk — proposals to modify or limit the stepped-up basis rules have been advanced repeatedly in Congress. |
| "I'll just set up a trust to avoid the capital gains tax." | The type of trust matters enormously. A revocable living trust is a grantor trust — the grantor pays all taxes directly, and no capital gains deferral occurs. A Charitable Remainder Trust (Strategy 05) offers genuine deferral but requires an irrevocable commitment and a charitable remainder. Offshore trust structures that purport to eliminate U.S. capital gains are generally either legally ineffective for U.S. citizens or constitute aggressive tax avoidance that carries serious IRS scrutiny and penalties. There is no domestic trust structure that simply eliminates capital gains on a business sale without either a charitable commitment or a genuine transfer of economic interest. |
| "I can avoid the NIIT by using an S-Corp." | Partially correct — but the mechanism matters. The 3.8% NIIT under IRC §1411 does not apply to gain from the sale of a business in which the taxpayer materially participates (IRC §469). This is an activity-based test, not an entity-based test. S-Corp status alone does not determine NIIT applicability; material participation does. An owner who is passive — or who has been passive in recent years — may be subject to the NIIT regardless of entity form. Confirm material participation status with your CPA before modeling after-tax proceeds at 20% rather than 23.8%. |
Every seller's situation is different. The right combination of strategies depends on deal structure, rollover appetite, tax basis, charitable intent, and the composition of the purchase price allocation. Use this matrix as a starting point — not a substitute for professional advice.
| Strategy | Tax Outcome | Best For | Key Limitation | Planning Lead Time |
|---|---|---|---|---|
| F-Reorganization (§368 + §721) | Defers rollover gain to exit | Deals with 20–40% rollover equity; S-Corp sellers | Requires buyer cooperation; deferred — not eliminated | 4–8 weeks before close |
| Installment Sale (§453) | Defers LTCG to future years | Deals with earnouts or seller notes | Ordinary income (A/R, recapture) cannot be deferred | Deal structure phase |
| Purchase Price Allocation (§1060) | Reduces effective rate | All sellers — highest leverage, lowest complexity | Buyer has opposing economic incentives on allocation | LOI through closing |
| Opportunity Zone Fund (§1400Z-2) | Defers then eliminates appreciation | Sellers with large LTCG wanting post-sale reinvestment flexibility | Must invest within 180 days; no control over fund deployment; Phase 1 deadline is Dec. 31, 2026 | Post-close (within 180 days) |
| Charitable Remainder Trust (§664) | Defers LTCG + reduces via deduction | Sellers with philanthropic intent; estate planning goals | Irrevocable; remainder to charity — not heirs | Months before closing; must precede binding sale and any active sale process — prearranged sale doctrine applies even without signed contract |
| Capital Loss Harvesting (§1211–1212) | Reduces net gain | Sellers with existing investment portfolio losses | Reduces — does not defer; wash sale rule applies | Same tax year as deal close |
The Sequencing Principle: These strategies are not mutually exclusive. A sophisticated seller closing in Q4 might simultaneously: (1) maximize goodwill allocation in the §1060 negotiation, (2) use an F-Reorg to defer tax on a 25% rollover, (3) use installment method treatment on a seller note (which applies automatically unless elected out), and (4) invest a portion of the cash proceeds into a QOF within 180 days of close. Each strategy operates independently on a different pool of gain. The total tax benefit can be additive — and the combined impact on a $5M+ deal can exceed seven figures in deferred or reduced federal tax liability. The strategies must be executed in the right sequence and with proper legal documentation. Early planning is essential.
Mihama does not provide tax or legal advice — but understanding these structures is core to how we negotiate and architect deals on behalf of sellers. Our role at each stage:
Mihama provides a complimentary tax-aware deal analysis for qualified healthcare practice owners — no retainer required. We work alongside your CPA and attorney to identify which strategies apply to your specific situation before you sign anything.
347-878-2941
Confidential, no obligation
info@mihamainc.com
Response within one business day
www.mihamainc.com
Resources & transaction experience